COMMUNIQUÉS West-GlobeNewswire

GENFIT Announces Launch of Proposed Global Offering and Nasdaq Listing
14/03/2019
FOR IMMEDIATE RELEASE GENFIT Announces Launch of Proposed Global Offering and Nasdaq Listing Lille (France), Cambridge (Massachusetts, United States), March 14, 2019 - GENFIT S.A. (Euronext Paris: GNFT - ISIN: [...]
GENFIT annonce le lancement de son introduction en bourse sur le Nasdaq dans le cadre d'une offre globale d'American Depositary Shares aux États-Unis et d'un Placement Privé d'actions
14/03/2019
CE COMMUNIQUÉ N'EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D'AMÉRIQUE NI A DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Aino Health AB (publ): Aino Health signs agreement worth around SEK 28 million
14/03/2019
2019-03-14 Aino Health has signed a customer agreement with one of the world's largest American multinational IT companies regarding its operations in Finland. The agreement means that Aino Health will be digitizing and [...]
Juneau Biosciences Gives Four Presentations at the 66th Annual Meeting of the Society for Reproductive Investigation (SRI)
14/03/2019
Juneau Biosciences reports its recent findings relating to the genetics of endometriosis in four presentations at SRI SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED [...]
SuperSonic Imagine pushes the boundaries of Breast Ultrasound Imaging with Aixplorer® MACH 30 presented at the NCoBC Breast Congress in Las Vegas
14/03/2019
The National Consortium of Breast Centers (NCoBC), Interdisciplinary Breast Center Conference, Las Vegas, March 15-20, 2019 Visit Supersonic Imagine at Booth # 105 at the NCoBC AIX-EN-PROVENCE, France, March 14, 2019 ( [...]
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
14/03/2019
Study is planned to assess efficacy and safety of Entresto ® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 Chagas disease is a [...]
Final transactions in relation to share buyback program
14/03/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates
14/03/2019
-- Anna Berkenblit, MD, appointed to Surrozen Board of Directors -- SAN FRANCISCO, March 14, 2019 (GLOBE NEWSWIRE) -- Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a [...]
Cannabix Technologies Provides Update on Marijuana Breathalyzer Development
14/03/2019
The Cannabix Marijuana Breathalyzer system is being developed to give law enforcement and employers a tool to enforce public safety. VANCOUVER, British Columbia, March 14, 2019 (GLOBE NEWSWIRE) -- Cannabix Technologies [...]
Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA
14/03/2019
Meeting with FDA scheduled for March 21, 2019 SOLANA BEACH, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI [...]
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
14/03/2019
WARREN, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported [...]
Fortress Biotech to Present at the 31st Annual ROTH Conference
14/03/2019
NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage [...]
Precision Therapeutics Extends Exchange Offer for Helomics Notes and Warrants
14/03/2019
MINNEAPOLIS, March 14, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced the extension of its previously announced offer (the “Exchange Offer”) to holders of [...]
Lobo Genetics and Alcanna Bring Genetic Testing to Alberta Cannabis Consumers
14/03/2019
TORONTO, March 14, 2019 (GLOBE NEWSWIRE) -- Lobo Genetics Inc. (“Lobo”), a leading cannabis healthcare technology company and Alcanna Inc. (“Alcanna”) (TSX: CLIQ), owner of Nova Cannabis and one of the largest private [...]
Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange
14/03/2019
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced an update with respect to its intention to voluntarily delist its ordinary shares, no [...]
Teligent, Inc. Announces FDA Approval of Desonide Ointment, 0.05%
14/03/2019
BUENA, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug [...]
Organovo to Participate in Nash Panel Discussion at 31st Annual Roth Conference
14/03/2019
SAN DIEGO, March 14, 2019 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that it will participate in a panel at the 31 st Annual ROTH Conference, being held in Laguna Niguel, Ca. [...]
Myriad’s myPath® Melanoma Test Receives Medicare Coverage
14/03/2019
Test Will Help Patients Receive a Definitive Diagnosis for a Suspicious Skin Lesion Biopsy SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized [...]
Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019
14/03/2019
EVANSTON, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]

Pages